RxDoctor Payments Data

Ambar Andrade

Advanced Heart Failure and Transplant Cardiology · Oak Lawn, ILNPI 1174751978

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,750 of the $35,344 with a category attached, or 70.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 66.7% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $16,888, 3.9 times the $4,386 reported in 2019.

$35,344in general payments, 2019–2025

Across 315 payments — averaging $112.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
  • Abbott$5K
  • Alnylam Pharmaceuticals Inc.$4K
  • Abiomed$2K
  • Medtronic$551
  • Novartis$137
  • plus $414 from 12 others

What the payments were for

  • Speaking & faculty fees$24,75070%
  • Travel & lodging$2,6788%
  • Food & beverage$7,89222%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,344 in reported general payments places this provider in the 65th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$51,923
Medicare patients
131
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan40$38,426
FarxigaDapagliflozin Propanediol31$27,464
JardianceEmpagliflozin25$18,150
EliquisApixaban11$13,942
Metoprolol Succinate43$792
Spironolactone68$687
Torsemide14$502
Atorvastatin Calcium17$155
Furosemide30$100
Carvedilol11$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$137$38,42640 claims
AstraZenecaFarxiga$62$27,46431 claims
Boehringer IngelheimJardiance$56$18,15025 claims
PfizerEliquis$21$13,94211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →